Please assess the completion status of the following clinical trial:

Trial Title: Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults \>18 yrs of age~* WHO defined MDS with Higher risk MDS (IPSS int-2/high)~* Azacitidine X at least 6 cycles with no hematologic improvement/no disease progression as per IWG 2006 criteria~* Ferritin \>500 µg/L~* If transfusion independent, must have Hb \<110 g/L OR Neutrophils \< 1,000/mL OR Platelets \< 100,000/mL~* ECOG ≤2~* CrCl \>40 ml/min~Exclusion Criteria:~* Increased ALT (\>300 U/L)~* Uncontrolled infection~* HIV+~* Pregnant or breast-feeding~* Previous and concurrent iron chelation~* Concurrent use of hematopoietic growth factors including erythropoietin, darbepoietin and granulocyte colony stimulating factor~* Concurrent use of other disease modifying agents including cytotoxic chemotherapy, histone deacetylase inhibitors, other hypomethylating agents or lenalidomide

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Deferasirox + Azacitidine (Type: EXPERIMENTAL): Azacitidine 75 mg/m2 daily X 7 days every 28 days for 6 cycles + Deferasirox 10-30 mg/kg/d depending on transfusion needs
- Azacitidine (Type: ACTIVE_COMPARATOR): Azacitidine 75 mg/m2 daily X 7 days every 28 days for 6 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).